The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium. (Q40703329)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

title

The Real-World Effectiveness and Safety of Vedolizumab for Moderate-Severe Crohn's Disease: Results From the US VICTORY Consortium (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

1 reference

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Arun Swaminath

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

John T Chang

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Edward V Loftus

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

3

Xiaoqian Jiang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

19

Bruce E Sands

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

William Jeffery Sandborn

18

object named as

William J Sandborn

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

author name string

Parambir S Dulai

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Siddharth Singh

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Farhad Peerani

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Neeraj Narula

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Khadija Chaudrey

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Diana Whitehead

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Dana Lukin

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Eugenia Shmidt

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Shuang Wang

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Brigid S Boland

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Sunanda Kane

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Corey A Siegel

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

Jean-Frederic Colombel

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

language of work or name

English

0 references

publication date

14 June 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

The American Journal of Gastroenterology

13 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

volume

111

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

page(s)

1147-1155

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

13 March 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management.

13 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

The risk of malignancy associated with the use of biological agents in patients with inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

Risks of serious infection or lymphoma with anti-tumor necrosis factor therapy for pediatric inflammatory bowel disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

Systematic review: Monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

Vedolizumab as induction and maintenance therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

Comparative efficacy of biologic therapy in biologic-naïve patients with Crohn disease: a systematic review and network meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

How Will Evolving Future Therapies and Strategies Change How We Position the Use of Biologics in Moderate to Severely Active Inflammatory Bowel Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

Assessment of mucosal healing in inflammatory bowel disease: review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

Pseudomonas Meningitis During Vedolizumab Therapy for Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

Efficacy of Vedolizumab as Induction Therapy in Refractory IBD Patients: A Multicenter Cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

Vedolizumab Effectiveness and Safety Over the First Year of Use in an IBD Clinical Practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

Vedolizumab induction therapy for inflammatory bowel disease in clinical practice--a nationwide consecutive German cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

Effects of vedolizumab induction therapy for patients with Crohn's disease in whom tumor necrosis factor antagonist treatment failed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

Association between plasma concentrations of certolizumab pegol and endoscopic outcomes of patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

A validated web-based tool to display individualised Crohn's disease predicted outcomes based on clinical, serologic and genetic variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

Systematic review with meta-analysis: the adverse effects of tobacco smoking on the natural history of Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

Current smoking differentially affects blood mononuclear cells from patients with Crohn's disease and ulcerative colitis: relevance to its adverse role in the disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

Effect of tumor necrosis factor-α blockade on mucosal addressin cell-adhesion molecule-1 in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

Infliximab, azathioprine, or combination therapy for Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FAJG.2016.236

Differential induction of VCAM-1 on human iliac venous and arterial endothelial cells and its role in adhesion.

21 January 2018

1 reference

12 December 2020

Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population

1 reference

12 December 2020

IOIBD technical review on endoscopic indices for Crohn's disease clinical trials

1 reference

12 December 2020

Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists

1 reference

12 December 2020

Identifiers

DOI

10.1038/AJG.2016.236

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27296941%20AND%20SRC:MED&resulttype=core&format=json

release_qym4lnfqa5fwzckt4crogfrr4e

13 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/qym4lnfqa5fwzckt4crogfrr4e

24 November 2022

mapped directly with Wikidata item

1 reference